Results 141 to 150 of about 170,256 (261)

Plasma Cell Mucositis: A 20‐Year Retrospective Review at a Tertiary Center

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes.
Miguel A. Aristizabal‐Torres, Jessi M. Larrinaga, Katherine Bodiford, Olayemi Sokumbi, Leila Tolaymat   +4 more
wiley   +1 more source

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo, Wei‐Chen Tai, Yen‐Hao Chen, Ming‐Chao Tsai, Jing‐Houng Wang, Sheng‐Nan Lu, Tsung‐Hui Hu, Chao‐Hung Hung, Chien‐Hung Chen, Yuan‐Hung Kuo   +9 more
wiley   +1 more source

Bilateral Ophthalmoplegia After Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma

The Laryngoscope, EarlyView.
The role of immune checkpoint inhibition (ICI) therapy in the treatment of head and neck squamous cell carcinoma (HNSCC) is expanding with increased utilization of neoadjuvant and adjuvant pembrolizumab in the setting of locally advanced disease. This report describes the presentation and management of the first known case of pembrolizumab‐induced ...
Leonard E. Estephan, Peter Jacoby, David M. Cognetti, Steven A. Manobianco   +3 more
wiley   +1 more source

Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials. [PDF]

ESMO Open
Cigliola A, Larcher A, Maiorano BA, Robesti D, Fallara G, Mercinelli C, Re C, Musso G, Cei F, Tateo V, Piacentini M, Bertini A, Disabato N, Piccolo C, Rosiello G, Briganti A, Necchi A, Montorsi F, Martini A, Capitanio U.   +19 more
europepmc   +1 more source

A pembrolizumab kezelés hatékonysága a recidiváló és metasztatikus méhnyakrák ellátásában

A pembrolizumab egy immunellenőrzőpont-gátló szer, amely a tumorsejt és a T-sejt interakciójában a programozott sejthalál ligand 1 (PD-L1) és receptora (PD-1) közötti kapcsolatot blokkolja és ezzel gátolja a daganattal szembeni immuntoleranciát.
Bodó, Krisztina
core  

Contemporary Treatment Patterns in Surgically Treated Temporal Bone Cancer

The Laryngoscope, EarlyView.
In a national cohort of 811 surgically treated temporal bone cancer patients, adjuvant radiation therapy was the most frequently utilized postoperative treatment (20.3%), while chemotherapy and immunotherapy were used far less frequently. Multimodal treatment, particularly combined parotidectomy and neck dissection, was strongly associated with higher ...
Raquel Rowell, Christopher Z. Wen, Vera Bzhilyanskaya, Jane Y. Tong, Adam C. Kaufman   +4 more
wiley   +1 more source

Precision medicine in cancer: A comprehensive review of advanced cancer diagnosis technologies and personalized treatment strategies

Precision Medical Sciences, EarlyView.
The translational pipeline of precision medicine in clinical oncology. Schematic overview of the individualized cancer care workflow. (1) Input: Patient samples undergo multi‐omic profiling via NGS, single‐cell diagnostics, spatial maps, and epigenetic sequencing.
Asif Jan, Bushra Waheed, Rani Akbar, Daniel Dubwa   +3 more
wiley   +1 more source

Current Perspectives on the Use of Adjuvant Pembrolizumab for Hepatocellular Carcinoma. [PDF]

J Hepatocell Carcinoma
Mingazzini A, Riado Minguez D, Babini Y, Gigante E, Bouattour M.   +4 more
europepmc   +1 more source

Radiation‐free or Chemo‐free: Rethinking the Best Strategy for PD‐L1‐High, Unresectable Stage III NSCLC

Precision Radiation Oncology, EarlyView.
This article discusses the emerging radiotherapy‐free and chemo‐free strategies in PD‐L1–high, unresectable stage III NSCLC, reviewing the Evolution trial and comparing it with existing treatments. We highlight the need for further research to validate these approaches and ensure safe de‐escalation without compromising ...
Yongbo Xiang, Nan Bi
wiley   +1 more source

Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR/MSI esophagogastric cancers? Results from the IMHOTEP phase II study. [PDF]

ESMO Open
Coutzac C, Zaanan A, de Montfort A, Soularue E, Cohen R, Le Sourd S, Piessen G, Hautefeuille V, Ben Abdelghani M, Blanc E, Svrcek M, Samalin E, Pérol D, de la Fouchardière C.   +13 more
europepmc   +1 more source